Runge S, Alte D, Baumeister SE, Völzke H. Prevalence of risk determinants for metformin-associated
lactic acidosis and metforminutilization in the study of health in pomerania. Horm
Metab Res 2008; 40: 491 – 497
During a follow-up analysis regarding the above-referenced article, an error in the
computer programme for coding the data was found. The NYHA classifi cation was wrongly
calculated which led to errors in 150 from 322 cases. This has been corrected and
leads to the changes listed below (highlighted in light grey):
Page 491:
Abstract
The prevalence of at least one risk determinant was 65% for metformin-users.
Page 493:
Risk determinants for metformin-associated lactic acidosis
The proportion of subjects with at least one risk determinant for metformin-associated
lactic acidosis was 65.2% in metformin users, 61.7% in subjects with alternative medication for type 2 diabetes mellitus, 58.8% in dietetically treated subjects. […] We identified three subjects among the metformin users who had three or more risk determinants for metformin-associated
lactic acidosis ([Table 3]).
Page 494:
Table 3 Number of risk determinants for metformin-associated lactic acidosis.
<TD VALIGN="TOP">
Number of risk determinants
</TD><TD VALIGN="TOP">
Metformin users n = 92
</TD><TD VALIGN="TOP">
Alternative drug treatment n = 162
</TD><TD VALIGN="TOP">
Dietetic treatment n = 68
</TD>
<TD VALIGN="TOP">
0
</TD><TD VALIGN="TOP">
32 (34.8)
</TD><TD VALIGN="TOP">
62 (38.3)
</TD><TD VALIGN="TOP">
28 (41.2)
</TD>
<TD VALIGN="TOP">
1
</TD><TD VALIGN="TOP">
45 (48.9)
</TD><TD VALIGN="TOP">
53 (32.7)
</TD><TD VALIGN="TOP">
26 (38.2)
</TD>
<TD VALIGN="TOP">
2
</TD><TD VALIGN="TOP">
12 (13.0)
</TD><TD VALIGN="TOP">
36 (22.2)
</TD><TD VALIGN="TOP">
12 (17.6)
</TD>
<TD VALIGN="TOP">
3
</TD><TD VALIGN="TOP">
3 (3.3)
</TD><TD VALIGN="TOP">
9 (5.6)
</TD><TD VALIGN="TOP">
2 (2.9)
</TD>
<TD VALIGN="TOP">
4
</TD><TD VALIGN="TOP">
0
</TD><TD VALIGN="TOP">
1 (0.6)
</TD><TD VALIGN="TOP">
0
</TD>
<TD VALIGN="TOP">
5
</TD><TD VALIGN="TOP">
0
</TD><TD VALIGN="TOP">
1 (0.6)
</TD><TD VALIGN="TOP">
0
</TD>
Table 4 (excerpt) Risk determinants for metformin-associated lactic acidosis of subjects treated with
metformin and subjects with alternative drug or dietetic treatment for type 2 diabetes
mellitus.
<TD VALIGN="TOP">
Risk determinant
</TD><TD VALIGN="TOP">
Condition
</TD><TD VALIGN="TOP">
Metformin users n = 92
</TD><TD VALIGN="TOP">
Alternative drug treatment n = 162
</TD><TD VALIGN="TOP">
Dietetic treatment n = 68
</TD>
<TD VALIGN="TOP">
tissue hypoxia
</TD><TD VALIGN="TOP">
severe heart failure or angina pectoris
</TD><TD VALIGN="TOP">
26 (28.3)
</TD><TD VALIGN="TOP">
55 (34.0)
</TD><TD VALIGN="TOP">
18 (26.5)
</TD>
Potential beneficiaries
A total number of 122 (37.9 %) subjects with type 2 diabetes mellitus had no risk determinants for metformin-associated
[…] Conversely, there were 62 (19.3 %) study participants with alternative drug treatment for type 2 diabetes mellitus without
risk determinants for metformin-associated lactic acidosis. Twenty-eight (45.2 %) of these subjects were obese (BMI ≥ 30 kg/m2) […]
